Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pentixafor
- Development stage
- Phase 2
- Lead developer
- Pentixapharm
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules, Peptides
- Administration
- Intravenous
01
Overview
Pentixafor is a peptide-based radiopharmaceutical imaging agent that targets the C-X-C chemokine receptor type 4 (CXCR4), a G-protein-coupled receptor overexpressed in various cancers and some benign tumors. It is primarily used as a tracer for positron emission tomography (PET) imaging after being labeled with gallium-68. Pentixafor binds specifically to CXCR4 on cancer cells, enabling sensitive and specific visualization of tumor burden and disease staging in conditions such as marginal zone lymphoma, multiple myeloma, lymphoma, neuroendocrine tumors, thymoma, leukemia, and adrenal gland disorders. The drug does not have therapeutic effects but serves as an advanced diagnostic tool for oncology and hematology applications. PentixaFor has received orphan drug designation from the European Medicines Agency for use in marginal zone lymphoma diagnosis and staging[1][4][5][7].
- Brand names
- PentixaFor
- Other names
- PentixaFor
02
Targets
CXCR4 (C-X-C motif chemokine receptor 4)
Beyond the preview
Go deeper on pentixafor.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pentixafor.